Subscribe To
GTBP / All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy
GTBP News
By Zacks Investment Research
June 2, 2023
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an more_horizontal
By Zacks Investment Research
May 19, 2023
All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy
GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might d more_horizontal
By GlobeNewsWire
February 24, 2023
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on develop more_horizontal
By PRNewsWire
January 20, 2022
GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference
BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing inno more_horizontal
By PRNewsWire
January 20, 2022
GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference
BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing inno more_horizontal
By PRNewsWire
January 20, 2022
GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference
BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing inno more_horizontal
By Seeking Alpha
November 15, 2021
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness more_horizontal
By Seeking Alpha
November 15, 2021
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness more_horizontal